Temple scientists target DNA repair to eradicate leukemia stem cells

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia , a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse.

http://www.innovations-report.com/html/reports/life_sciences/temple_scientists_target_dna_repair_eradicate_206966.html